CYNTHIA HEYNE: Open Payments
NPI 1831588185 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 13 payments from 9 companies in 2025. Trend: 2023 $374 · 2024 $387 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $248 |
| Teva Pharmaceuticals USA, Inc. | 3 | $160 |
| Novo Nordisk Inc | 1 | $125 |
| CVRx, Inc. | 1 | $106 |
| Neurocrine BioSciences, Inc. | 2 | $66 |
| Lilly USA, LLC | 1 | $30 |
| Ardelyx, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: FANAPT, AUSTEDO XR, Barostim Neo System, INGREZZA, AMYVID, IBSRELA, Briviact, REXULTI.
Industry payments across FL — which companies pay providers there.
